Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Redefining the Concept of Clinically Insignificant Prostate Cancer.

Frankcombe DE, Li J, Cohen RJ.

Urology. 2019 Nov 9. pii: S0090-4295(19)30964-1. doi: 10.1016/j.urology.2019.10.019. [Epub ahead of print]

PMID:
31715271
2.

Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.

Özsoy M, D'Andrea D, Moschini M, Foerster B, Abufaraj M, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, Shariat SF.

Urol Oncol. 2018 Apr;36(4):158.e1-158.e6. doi: 10.1016/j.urolonc.2017.12.003. Epub 2017 Dec 27.

PMID:
29288003
3.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

4.

Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.

O'Neil LM, Walsh S, Cohen RJ, Lee S.

BJU Int. 2015 Oct;116 Suppl 3:42-8. doi: 10.1111/bju.13173. Epub 2015 Jul 27.

5.

Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.

Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC.

BJU Int. 2016 Aug;118(2):250-7. doi: 10.1111/bju.13319. Epub 2015 Oct 8.

6.

Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score.

Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat SF, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK.

BJU Int. 2014 Mar;113(3):399-407. doi: 10.1111/bju.12424. Epub 2013 Dec 2.

7.

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.

BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x. Epub 2013 Jan 25.

8.

Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.

Ritch CR, Morrison BF, Hruby G, Coard KC, Mayhew R, Aiken W, Benson MC, McKiernan JM.

BJU Int. 2013 Apr;111(4 Pt B):E186-90. doi: 10.1111/j.1464-410X.2012.11540.x. Epub 2012 Oct 26.

9.
10.

Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

Chen DJ, Falzarano SM, McKenney JK, Przybycin CG, Reynolds JP, Roma A, Jones JS, Stephenson A, Klein E, Magi-Galluzzi C.

BJU Int. 2015 Aug;116(2):220-9. doi: 10.1111/bju.12880. Epub 2014 Dec 15.

11.

Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men.

Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, Jeong SJ, Yoon CY, Byun SS, Choe G, Hwang SI, Lee HJ, Hong SK.

BJU Int. 2010 Jun;105(11):1526-30. doi: 10.1111/j.1464-410X.2009.09070.x. Epub 2009 Nov 13.

12.

Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.

Chondros Κ, Karpathakis Ν, Heretis Ι, Mavromanolakis Ε, Chondros N, Sofras F, Mamoulakis C.

Hippokratia. 2015 Jan-Mar;19(1):30-3.

13.

Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.

Ting F, van Leeuwen PJ, Delprado W, Haynes AM, Brenner P, Stricker PD.

Prostate. 2015 Nov;75(15):1768-73. doi: 10.1002/pros.23062. Epub 2015 Aug 18.

PMID:
26282713
14.

New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.

Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.

Eur Urol. 2017 Jun;71(6):907-912. doi: 10.1016/j.eururo.2016.11.006. Epub 2016 Nov 19.

PMID:
27876305
15.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

16.

Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer.

Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso P.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):221-227. doi: 10.1038/s41391-017-0019-4. Epub 2017 Dec 11.

PMID:
29230008
17.

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.

Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG.

BJU Int. 2012 Jun;109(12):1794-800. doi: 10.1111/j.1464-410X.2011.10572.x. Epub 2011 Oct 12.

18.

Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.

Choy B, Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE, Paner GP.

Am J Surg Pathol. 2016 Oct;40(10):1400-6. doi: 10.1097/PAS.0000000000000691.

PMID:
27379821
19.

Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.

Carter HB, Sauvageot J, Walsh PC, Epstein JI.

J Urol. 1997 Jun;157(6):2206-9. Review.

20.

Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.

Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewicz PI.

BJU Int. 2011 Mar;107(5):765-770. doi: 10.1111/j.1464-410X.2010.09594.x. Epub 2010 Sep 28.

Supplemental Content

Support Center